Rodis Jennifer L, Kibbe Pamella
The Ohio State University College of Pharmacy, Columbus, OH 43210, USA.
Gastroenterol Nurs. 2010 Sep-Oct;33(5):368-73. doi: 10.1097/SGA.0b013e3181f443cb.
The purpose of this study was to identify medication adherence for patients infected with hepatitis C virus (HCV) referred to an interdisciplinary HCV education and monitoring service, evaluate changes in quality of life (QOL) and medication adherence during the first 3 months of HCV therapy, and determine relationships between adherence and QOL. Patients completed an initial survey before initiating the therapy evaluating medication adherence and QOL. They then received a structured training on HCV medications and monthly monitoring phone call from a pharmacist throughout the therapy. After 3 months of treatment, a follow-up survey was conducted to evaluate adherence, satisfaction, and QOL. Medication adherence was also assessed via patient self-report during follow-up phone calls. Patients expressed satisfaction with the care provided by the pharmacist and nurse practitioner individually and working collaboratively during their HCV therapy. Patients reported taking 99.8% of total interferon and ribavirin doses during the first 3 months of the therapy. Patients who indicated that they sometimes stopped taking medication when they felt worse had higher median aggregate physical functioning scores (p = .04) and those with no comorbidities found dosage times more inconvenient than those with at least one comorbidity (p = .046). Patients in a pharmacist-run HCV education service have high self-reported adherence rates and are satisfied with the interdisciplinary model of care. Quality of life may be associated with adherence; higher functioning, healthier patients may be more likely to stop taking HCV medications owing to side effects or inconvenience.
本研究的目的是确定转诊至跨学科丙型肝炎病毒（HCV）教育与监测服务机构的HCV感染患者的药物依从性，评估HCV治疗前3个月生活质量（QOL）和药物依从性的变化，并确定依从性与QOL之间的关系。患者在开始治疗前完成了一项初始调查，评估药物依从性和QOL。然后，他们接受了关于HCV药物的结构化培训，并在整个治疗过程中每月接到药剂师的监测电话。治疗3个月后，进行了一项随访调查，以评估依从性、满意度和QOL。在随访电话中，还通过患者自我报告评估了药物依从性。患者对药剂师和执业护士在其HCV治疗期间单独提供的护理以及合作提供的护理表示满意。患者报告在治疗的前3个月中服用了99.8%的干扰素和利巴韦林总剂量。表示有时在感觉更糟时会停止服药的患者，其总体身体功能得分中位数更高（p = 0.04），且无合并症的患者比至少有一种合并症的患者觉得给药时间更不方便（p = 0.046）。参加药剂师管理的HCV教育服务的患者自我报告的依从率较高，并对跨学科护理模式感到满意。生活质量可能与依从性相关；功能更好、更健康的患者可能由于副作用或不便而更有可能停止服用HCV药物。
